Literature DB >> 158106

[Decreased serum protein binding of glymidine in icteric liver disease and its partial correction with charcoal (author's transl].

H Held.   

Abstract

In patients with hyperbilirubinemic liver disease serum protein binding of the antidiabetic agent glymidine is reduced considerably. After treatment of the serum with charcoal the reduced glymidine binding can be assimilated partly, but not completely, to the glymidine binding in healthy subjects. It may be concluded there from that the reduced glymidine binding in patients with hyperbilirubinemic liver disease has to be partly caused by substances which are retained in the blood of these patients. Besides bilirubin, other substances must be responsible herefore. Bilirubin, when added in vitro to the serum of healthy subjects, is not able to decrease glymidine binding to a degree similar to the results obtained in the patients with liver disease.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 158106     DOI: 10.1007/bf01477670

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  11 in total

1.  The protein binding of some drugs in plasma from patients with alcoholic liver disease.

Authors:  M Affrime; M M Reidenberg
Journal:  Eur J Clin Pharmacol       Date:  1975-04-04       Impact factor: 2.953

2.  The alteration of plasma proteins in uremia as reflected in their ability to bind digitoxin and diphenylhydantoin.

Authors:  D W Shoeman; D L Azarnoff
Journal:  Pharmacology       Date:  1972       Impact factor: 2.547

3.  Plasma protein binding of diphenylhydantoin in normal and hyperbilirubinemic infants.

Authors:  A Rane; P K Lunde; B Jalling; S J Yaffe; F Sjöqvist
Journal:  J Pediatr       Date:  1971-05       Impact factor: 4.406

4.  [Spectrofluorometric method for determination of glycodiazine in plasma and of the both glycodiazine metabolites in urine].

Authors:  H Held; B Kaminski; H F von Oldershausen
Journal:  Arzneimittelforschung       Date:  1970-12

5.  [Protein binding of bilirubin and bromsulfalein].

Authors:  W Scholtan; C Gloxhuber
Journal:  Arzneimittelforschung       Date:  1966-04

6.  Removal of fatty acids from serum albumin by charcoal treatment.

Authors:  R F Chen
Journal:  J Biol Chem       Date:  1967-01-25       Impact factor: 5.157

7.  [Pharmacokinetics of glymidine (glycodiazine) and tolbutamide in acute and chronic liver diseases].

Authors:  H Held; R Eisert; H F von Oldershausen
Journal:  Arzneimittelforschung       Date:  1973-12

8.  [2-BENZENESULFONAMIDO-5-(2-METHOXYETHOXY)-PYRIMIDINE (GLYCODIAZIN), A NEW BLOOD SUGAR-LOWERING AGENT. I. THE METABOLISM OF GLYCODIAZIN IN MAN].

Authors:  E GERHARDS; H GIBIAN; K H KOLB
Journal:  Arzneimittelforschung       Date:  1964-05

9.  Correction of protein binding defect in uremic sera by charcoal treatment.

Authors:  W A Craig; M A Evenson; K P Sarver; J P Wagnild
Journal:  J Lab Clin Med       Date:  1976-04

10.  Competitive binding of bilirubin and drugs to human serum albumin studied by enzymatic oxidation.

Authors:  R Brodersen
Journal:  J Clin Invest       Date:  1974-12       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.